Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$301,743 | $49,271 | -$198,375 | -$87,931 |
| Dep. & Amort. | $904 | $1,088 | $487 | $52 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $33,038 | $0 | $21,714 | $3,136 |
| Change in WC | -$45,831 | -$65,661 | -$1,641 | $4,595 |
| Other Non-Cash | $145,985 | $27,221 | -$2,056 | $5,349 |
| Operating Cash Flow | -$167,647 | $11,919 | -$179,871 | -$74,799 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$157 | -$1,241 | -$2,526 | -$353 |
| Net Acquisitions | $0 | $0 | $236,462 | $0 |
| Inv. Purchases | -$231,986 | -$300,826 | -$415,873 | -$49,053 |
| Inv. Sales/Matur. | $344,000 | $394,120 | $179,411 | $3,000 |
| Other Inv. Act. | -$36,203 | $0 | -$236,462 | $0 |
| Investing Cash Flow | $75,654 | $92,053 | -$238,988 | -$46,406 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $25,896 |
| Stock Issued | $2,132 | $6,858 | $432,447 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$1,784 | -$3,315 | -$658 | $132,610 |
| Financing Cash Flow | $348 | $3,543 | $431,789 | $158,506 |
| Forex Effect | -$438 | $160 | -$65 | $13 |
| Net Chg. in Cash | -$92,083 | $107,675 | $12,865 | $37,314 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $170,920 | $62,526 | $50,380 | $13,066 |
| End Cash | $78,837 | $170,201 | $63,245 | $50,380 |
| Free Cash Flow | -$167,804 | $10,678 | -$182,397 | -$75,152 |